THWM
BMRN icon

Taylor Hoffman Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Taylor Hoffman Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$7K – 420
2019
Q3 		$7K Hold
100
– – 0.01% 328
2019
Q2 		$9K Hold
100
– – 0.01% 293
2019
Q1 		$9K Hold
100
– – 0.01% 292
2018
Q4 		$9K Buy
+100
New +$9.51K 0.01% 284

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Taylor Hoffman Wealth Management's BMRN Position: Q4 2019 in Review

Taylor Hoffman Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 100 shares — an estimated $7K sold.

Taylor Hoffman Wealth Management first reported a position in BMRN in Q4 2018 and held it in 4 quarters. The position peaked at $9K in Q2 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Taylor Hoffman Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Taylor Hoffman Wealth Management sold 100 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $7K.
  • Taylor Hoffman Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Taylor Hoffman Wealth Management's BioMarin Pharmaceuticals position peaked at $9K in Q2 2019.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Taylor Hoffman Wealth Management's 13F filing for Q4 2019, filed 11 Feb 2020.